SUMMARY
The aim of the study – to observe the relationship between serum levels of interleukin 8 (IL-8), C-reactive protein (CRP) and lung function in patients with chronic obstructive pulmonary disease (COPD). Materials and methods. The prospective study involved 122 patients with an established diagnosis of COPD (main group) and 20 patients without this disease and other pulmonary and severe somatic diseases (control group). The selection of patients in the polyclinic was carried out during spontaneous routine or scheduled visits. Selected study participants completed COPD questionnaires (Chronic Airways Diseases, A Guide for Primary Care Physicians, 2005; COPD Assessment Test) and underwent a complete examination, after which they were diagnosed with COPD. Spirometry was performed using a portable ultrasonic spirometer. The level of IL-8 in the blood was determined by ELISA, CRP - immunoturbidimetric method. Results. The average age of patients with COPD was 55.9±4.4 years, men accounted for 59.0%, women – 41.0%, smokers – 57.4%. The indices of FEV1, FVC and FEV1/FVC in patients with COPD were lower than the control values by 55.72% (p=0.001), 43.23% (p=0.001), and 35.28% (p=0.036), respectively. The concentration of CRP and IL-8 exceeded the control by 66.30% (p=0.015) and 35.33% (p=0.001), respectively. CRP correlated with FEV1 mean feedback (r=-0.699, p<0.01), FVC (r=-0.702, p<0.01) and FEV1/FVC (r=-0.756, p<0.01) strong connection. IL-8 correlated strongly with all parameters of lung function: with FEV1 – r=-0.801 (p<0.001); with FVC – r=-0.711 (p<0.01); with FEV1/FVC – r=-0.730 (p<0.01). Conclusion. The results obtained confirmed elevated levels of inflammatory markers and the presence of a statistically significant strong inverse correlation between these markers and lung function parameters. Further studies are needed to confirm the results and make recommendations for identifying clinical phenotypes.
Keywords: chronic obstructive pulmonary disease, inflammation markers, lung function parameters, correlation

---

REFERENCES

1. Haroon S, Jordan R, Takwoingi Y, Adab P. Diagnosticaccuracyofscreening tests for COPD: a systematic review and meta-analysis // BMJ Open. 2015;5: e008133. doi: 10.1136/bmjopen-2015-008133.
2. García-Sidro P, Naval E, Rivera C.M. et al. The CAT (COPD Assessment Test) questionnaire as a predictor of the evolution of severe COPD exacerbations // Respiratory Medicine. 2015; 109(12):1546-1552. doi: 10.1016/ j.rmed. 2015.10.011.
3. Garcia-Rio F, Miravitlles M, Soriano J.B. et al. Systemic inflammation in chronic obstructive pulmonary disease: a population-based study // Respir Res. 2010;11:63. doi: 10.1186/1465-9921-11-63.
4. Su B, Liu T, Fan H, Chen F. et al. Inflammatory Markers and the Risk of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis // PLoS ONE. 2016;11(4): e0150586. doi: 10.1371/journal.pone.0150586.
5. Hlapčić I, Belamarić D, Bosnar M, Kifer D, Dugac AV, Rumora L. Combination of Systemic Inflammatory Biomarkers in Assessment of Chronic Obstructive Pulmonary Disease: Diagnostic Performance and Identification of Networks and Clusters // Diagnostics. 2020; 10(12): 1029. doi: 10.3390/diagnostics10121029.
6. Wang XR, Li YP, Gao S, Xia W, et al. Increased serum levels of lipocalin-1 and -2 in patients with stable chronic obstructive pulmonary disease // Int J Chron Obstruct Pulmon Dis., 2014; 9: 543–549. doi: 10.2147/COPD.S62700.
7. Fattouh M, Alkady O. Inflammatory biomarkers in chronic obstructive pulmonary disease // Egyptian Journal of Chest Diseases and Tuberculosis. 2014; 63: 799–804. doi:10.1016/ j.ejcdt.2014.06.011.
8. Harting JR, Gleason A, Romberger DJ, Von Essen SG, Qiu F, Alexis N, et al. Chronic obstructive pulmonary disease patients have greater systemic responsiveness to ex vivo stimulation with swine dust extract and its components versus healthy volunteers // J ToxicolEnvironHealth A. 2012; 75: 1456–1470.doi: 10.1080/15287394.2012.722186.
9. Stockley RA. Biomarkers in chronic obstructive pulmonary disease: confusing or useful? // Int. J. COPD. 2014;9:163-177. doi: 10.2147/COPD.S42362.
10. Agusti А, Edwards LD, Rennard SI, MacNee W, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS ONE. 2012;7(5):e37483. doi: 10.1371/journal.pone.0037483.
11. Shahriary A, Panahi Y, Shirali S, Rahmani H. Relationship of serum levels of interleukin 6, interleukin 8, and C-reactive protein with forced expiratory volume in first second in patients with mustard lung and chronic obstructive pulmonary diseases: systematic review and meta-analysis // Postepy Dermatol Alergol. 2017; 34(3): 192–198. doi: 10.5114/ada.2017.67841.
12. Liu SF, Wang CC, Chin CH, Chen YC, Lin MC. High value of combined serum C-reactive protein and BODE score for mortality prediction in patients with stable COPD Arch // Bronconeumol. 2011;47:427-432. doi:10.1016/j.arbres.2011.04.011.
13. Heidari B. The importance of C-reactive protein and other inflammatory markers in patients with chronic obstructive pulmonary disease // Caspian J Intern Med. 2012;3(2):428–435.
14. Sin DD, Man SF. Systemic inflammation and mortality in chronic obstructive pulmonary disease // Can J Physiol Pharmacol. 2007;85(1):141-7. doi: 10.1139/y06-093.
15. Morello Gearhart A., Cavallazzi R., Peyrani P. et al. Lung Cytokines and Systemic Inflammation in Patients with COPD // J. Respir. Infect. 2017; 1(4): 13-18.doi: 10.18297/jri/vol1/iss4/4.
16. Zhang J, Bai C. Elevated serum IL-8: a biomarker indicating exacerbation-prone COPD // European Respiratory Journal. 2017;50: PA3601. doi: 10.1183/1393003.congress-2017.PA3601.